Understand the source comparison
Peptides for Meniscus Recovery Protocol Evidence Guide: Comparison
BPC-157 FAK-paxillin pathway activation; promotes fibroblast migration and collagen deposition 250–500 mcg/day subcutaneous Animal models only (rats, rabbits); no human RCTs Well-tolerated in animal studies; human adverse event data unavailable No FDA-approved
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- FAK-paxillin pathway activation; promotes fibroblast migration and collagen deposition
- 250–500 mcg/day subcutaneous
- Animal models only (rats, rabbits); no human RCTs
- Well-tolerated in animal studies; human adverse event data unavailable
- No FDA-approved trials; classified as research compound
- TB-500
- G-actin binding; VEGF upregulation for angiogenesis
- 2–5 mg/week subcutaneous
- Equine veterinary use; rodent soft tissue models
- Injection site reactions reported in veterinary use; systemic effects unknown
- No human clinical trials for musculoskeletal indications
- MK-677
- Growth hormone secretagogue; increases IGF-1
- 10–25 mg/day oral
- Phase II trials for muscle wasting; no meniscus-specific studies
- Increased appetite, transient insulin resistance
- FDA orphan drug designation for growth hormone deficiency
- Standard Physiotherapy
- Progressive loading, neuromuscular retraining
- 8–12 weeks structured rehabilitation
- Established standard of care; Level I evidence
- Minimal risk; dependent on adherence
- N/A (non-pharmacological intervention)